Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety Review


Authors: Williamson, C. W.; Sherer, M. V.; Zamarin, D.; Sharabi, A. B.; Dyer, B. A.; Mell, L. K.; Mayadev, J. S.
Review Title: Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety
Abstract: Radiation therapy exerts a tumoricidal local effect as well as both local and systemic immunomodulation. Immune checkpoint blockade has become a widely used treatment modality across cancer types with a rapidly growing list of agents and US Food and Drug Administration-approved indications. Moreover, there may be synergy between radiation therapy and immune checkpoint blockade. Various strategies have been used, but the optimal sequencing of these therapies is unclear. In this review, the authors discuss the major mechanisms of available immune checkpoint inhibitors and explore the available preclinical and clinical evidence regarding treatment sequencing. They also review safety considerations and conclude with possible future directions. © 2021 American Cancer Society
Keywords: cancer survival; drug tolerability; review; bevacizumab; nonhuman; cancer radiotherapy; ipilimumab; ticilimumab; cancer immunotherapy; cetuximab; prostate cancer; clinical study; immune response; immunotherapy; head and neck cancer; glioblastoma; uterine cervix cancer; patient safety; soft tissue sarcoma; radiation therapy; toxicity; cytotoxic t lymphocyte antigen 4; transitional cell carcinoma; radiosensitization; programmed death 1 receptor; non small cell lung cancer; metastatic melanoma; head and neck squamous cell carcinoma; clinical outcome; immune checkpoint blockade; synergistic effect; preclinical study; nivolumab; human; priority journal; pembrolizumab; durvalumab; atezolizumab; cancer therapy sequencing
Journal Title: Cancer
Volume: 127
Issue: 10
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2021-05-15
Start Page: 1553
End Page: 1567
Language: English
DOI: 10.1002/cncr.33424
PUBMED: 33620731
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 June 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dmitriy Zamarin
    201 Zamarin